An Analog Classroom Study: Efficacy and Safety of SPN-812 in Children With Attention-Deficit/Hyperactivity Disorder
Latest Information Update: 19 Sep 2019
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
Most Recent Events
- 17 Sep 2019 Status changed from not yet recruiting to withdrawn prior to enrollement due to non-safety related corporate decision.
- 15 Jul 2019 New trial record